NCT04258683 2023-08-29A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTECanadian Myeloma Research GroupPhase 2 Withdrawn